Modalis Therapeutics Corporation (JP:4883)
:4883
Want to see JP:4883 full AI Analyst Report?
4883 Stock Chart & Stats
¥56.00
-¥3.00(-2.91%)
At close: 4:00 PM EST
¥56.00
-¥3.00(-2.91%)
Day’s Range― - ―
52-Week Range¥32.00 - ¥103.00
Previous CloseN/A
Volume5.80M
Average Volume (3M)719.68K
Market Cap
¥3.28B
Enterprise Value¥1.52B
Total Cash (Recent Filing)¥3.26B
Total Debt (Recent Filing)¥0.00
Price to Earnings (P/E)―
Beta>-0.01
Next Earnings
Aug 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-24.01
Shares Outstanding96,334,100
10 Day Avg. Volume617,120
30 Day Avg. Volume719,680
Financial Highlights & Ratios
PEG Ratio0.81
Price to Book (P/B)1.55
Price to Sales (P/S)0.00
P/FCF Ratio-2.04
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-22.2
Revenue Forecast (FY)¥800.00M
Bulls Say, Bears Say
Bulls Say
Low Reported DebtThe absence of reported debt in 2024–2025 materially reduces near-term financing cost and default risk, giving management flexibility to prioritize R&D and partnership strategies. Over a multi-month horizon, low leverage supports capital allocation optionality during continued clinical development.
Platform-focused R&DA dedicated gene expression–modulating platform creates a durable technical moat versus one-off programs: it can generate multiple candidates across genetic indications, support licensing or partnerships, and concentrate scientific IP and expertise that sustain long-term value creation independent of short-term market moves.
Transparent Cash AccountingFree cash flow tracking closely to net loss indicates limited non-cash distortion in earnings, improving visibility into true cash burn. For investors and partners this reduces accounting risk and makes runway and financing needs more predictable over coming months, aiding long-term planning.
Bears Say
Minimal-to-zero RevenueThe company remains pre-commercial with essentially no revenue for multiple years, meaning no operating cash generation to fund activities. Over the medium term this forces reliance on external capital, delays structural margin improvement, and leaves commercial execution and reimbursement risk unproven.
Persistent Cash BurnConsistent negative operating and free cash flow signifies ongoing funding dependence; worsening 2025 cash outflows tighten runway and heighten dilution risk. Structurally, recurring cash burn constrains strategic optionality and increases vulnerability to capital market conditions over the next several months.
Eroding Shareholder EquityMaterial equity erosion from cumulative losses reduces the company's financial buffer and borrowing capacity. Over a durable horizon this weakens balance-sheet resilience, limits strategic flexibility for partnerships or M&A, and amplifies downside risk if additional funding access tightens.
Modalis Therapeutics Corporation News
4883 FAQ
What was Modalis Therapeutics Corporation’s price range in the past 12 months?
Modalis Therapeutics Corporation lowest stock price was ¥32.00 and its highest was ¥103.00 in the past 12 months.
What is Modalis Therapeutics Corporation’s market cap?
Modalis Therapeutics Corporation’s market cap is ¥3.28B.
When is Modalis Therapeutics Corporation’s upcoming earnings report date?
Modalis Therapeutics Corporation’s upcoming earnings report date is Aug 12, 2026 which is in 61 days.
How were Modalis Therapeutics Corporation’s earnings last quarter?
Modalis Therapeutics Corporation released its earnings results on May 14, 2026. The company reported -¥3.64 earnings per share for the quarter, missing the consensus estimate of N/A by -¥3.64.
Is Modalis Therapeutics Corporation overvalued?
According to Wall Street analysts Modalis Therapeutics Corporation’s price is currently Overvalued.
Does Modalis Therapeutics Corporation pay dividends?
Modalis Therapeutics Corporation does not currently pay dividends.
What is Modalis Therapeutics Corporation’s EPS estimate?
Modalis Therapeutics Corporation’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Modalis Therapeutics Corporation have?
Modalis Therapeutics Corporation has 96,334,100 shares outstanding.
What happened to Modalis Therapeutics Corporation’s price movement after its last earnings report?
Modalis Therapeutics Corporation reported an EPS of -¥3.64 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 3.03%.
Which hedge fund is a major shareholder of Modalis Therapeutics Corporation?
Currently, no hedge funds are holding shares in JP:4883
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Modalis Therapeutics Corporation
Modalis Therapeutics Corporation focuses on discovering and developing treatments for severe genetic conditions. The company utilizes its proprietary CRISPR-GNDM technology to create therapies by controlling gene expression through the epigenetic modulation of specific genetic loci. Modalis also has a collaborative research agreement with JCR Pharmaceuticals Co., Ltd., aimed at assessing gene therapy drug delivery methods for the central nervous system (CNS), particularly for CNS-related disorders. Founded in 2016, the company was initially known as EdiGENE Corporation before changing its name to Modalis Therapeutics Corporation in August 2019. Its operations are based in Tokyo, Japan.
Technical Analysis
Solasia Pharma KK
―
Nippon Chemiphar Co., Ltd.
―
Taiko Pharmaceutical Co., Ltd.
―
Symbio Pharmaceuticals Limited
―
Cyfuse Biomedical K.K.
―